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Abstract
Background: The human gastrointestinal (GI) tract microbiota has been a subject of intense research throughout
the 3rd Millennium. Now that a general picture about microbiota composition in health and disease is emerging,
questions about factors determining development of microbiotas with specific community structures will be
addressed. To this end, usage of murine models for colonization studies remains crucial. Optical in vivo imaging of
either bioluminescent or fluorescent bacteria is the basis for non-invasive detection of intestinal colonization of
bacteria. Although recent advances in in vivo fluorescence imaging have overcome many limitations encountered
in bioluminescent imaging of intestinal bacteria, such as requirement for live cells, high signal attenuation and 2D
imaging, the method is still restricted to bacteria for which molecular cloning tools are available.
Results: Here, we present usage of a lipophilic fluorescent dye together with Katushka far-red fluorescent protein
to establish a dual-color in vivo imaging system to monitor GI transit of different bacterial strains, suitable also for
strains resistant to genetic labeling. Using this system, we were able to distinguish two different E. coli strains
simultaneously and show their unique transit patterns. Combined with fluorescence molecular tomography, these
distinct strains could be spatially and temporally resolved and quantified in 3D.
Conclusions: Developed novel method for labeling microbes and identify their passage both temporally and
spatially in vivo makes now possible to monitor all culturable bacterial strains, also those that are resistant to
conventional genetic labeling.
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Fluorescence molecular tomography, Murine model, Far-red fluorescent protein, In vivo, Intestine
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: justus.reunanen@oulu.fi
†Oula Peñate-Medina and Robert J. Tower contributed equally to this work.
10Biocenter Oulu & Cancer and Translational Medicine Research Unit,
University of Oulu, Aapistie 5, 90220 Oulu, Finland
Full list of author information is available at the end of the article
Peñate-Medina et al. BMC Microbiology          (2019) 19:167 
https://doi.org/10.1186/s12866-019-1538-z
Background
A wealth of knowledge about microbiota composition in
the gastrointestinal tract (GI-tract) has been gained from
large international efforts such as the MetaHIT and the
Human Microbiome Project [1]. These studies have
revealed the microbial world within each of us to be com-
posed of hundreds of species, with the whole microbial
catalogue of the human GI-tract being made up thousands
of bacterial species [2], out of which more than 1000
species have been cultured [3]. Our microbiota serves us
in many ways, e.g. by fermenting nutrients otherwise un-
digestible, by synthesizing vitamins, and by out-competing
pathogens [4, 5]. Reduction in diversity and changes in
microbiota composition have been linked to GI-tract ill-
nesses, such as ulcerative colitis and Crohn’s disease [6, 7].
Moreover, distinctive microbiota patterns have also been
associated with diet-induced systemic disorders, such as
obesity [8–10], metabolic syndrome [11, 12], type II dia-
betes [13] and cardiovascular disease [14], indicating the
importance of GI-tract function in systemic health. Ac-
cording to the current scheme, the resilience provided by
a “healthy”microbiota can be gradually deteriorated by ex-
ternal disturbances such as a high-fat diet or antibiotic
use, which, in the onset of malignant processes, perturbs
the GI-tract ecosystem leading to reduced microbiota di-
versity, low grade inflammation, and ultimately chronic
disease development [5].
The concept of enterotypes was recently introduced by
Arugaman et al., who used a combinatorial approach to
analyze metagenomic data sets of 39 individuals from 4
countries in 3 different continents [15]. According to the
authors, there are three robust bacterial clusters, the
enterotypes, found in the GI-tract microbiomes across
the human population, which are independent of the
nation or continent of origin. Each of these enterotypes
are built around stable bacterial communities composed
of a limited number of species, suggesting that variations
in microbiota structures between individuals are strati-
fied rather than continuous. An important consequence
of this observation is that there are a limited number of
different stable host-microbial species combinations, and
therefore a limited amount of symbiotic or mutualistic
host-microbiota states that could differentially respond
to external stimuli such as diet or medication. Based on
metagenomic data sets and solid patterns of co-existing
and negatively-correlating microbial genera (e.g. Akker-
mansia and Ruminococci), the enterotypes are assumed
to be built upon trophic metabolic chains [15]. A choice
between different enterotypes seems to be environmen-
tally and microbially driven rather than determined by
host genetics, since the core forming genera of each
different enterotypes were found in all human subjects
analyzed [16]. Furthermore, in a long-term follow-up
study of more than 10 years, it was observed that
individual’s microbiota can switch enterotype over time
[17]. These findings, combined with data from patients
treated for recurrent Clostridium difficile colitis [18] and
insulin insensitivity [19] by fecal transplantation, support
the emerging concept of personalized microbiota modula-
tion as a future therapy to treat multiple disorders [20].
Despite the increasing body of evidence from human
cohorts linking microbiota aberrations with major hu-
man diseases, most of the functional proof-of-concepts
on the role of microbiota and its individual members in
health and disease have been obtained from mouse
intervention studies using gnotobiotic (germ-free) mice
[21]. The gnotobiotic mouse model continues to be
instrumental in the study of the microbiota’s effects on
host physiology and health, since it offers a reductionis-
tic (both in terms of microbiota and host genetics) in
vivo model, in which the effects of pre-designed minimal
microbiota, composed of a single or a few species only,
can be monitored. To date, the monitoring of bacterial
species and strains in the mouse GI-tract has been based
on either in vivo bioluminescence or fluorescence of
genetically labeled strains, in vitro analysis of fecal sam-
ples, or ex vivo analysis of resected intestinal tissue. All
these approaches are subject to several drawbacks: i)
bioluminescent imaging of bacteria in the GI tract has
been limited to 2-dimensional imaging and thus poor
spatial resolution [22–24], ii) high tissue absorption of
fluorescent signal at wavelengths below the far-red area
of the visible spectrum iii) fluorescence imaging with
near-infrared fluorescent proteins requires addition of
biliverdin, an exogenous chromophore needed for fluor-
escence development [25] iv) fecal samples reflect co-
lonic microbiota only, whereas microbiota composition
and function differ markedly between the small intestine
and colon [19, 26–28], v) resected tissues represent end-
point analysis only, which disregards dynamic fluctua-
tions in host-microbe and microbe-microbe relation-
ships over time [29]. The dual-color fluorescent labeling
method presented herein, using either genetically
encoded Katushka far-red fluorescent protein or mem-
brane-labeling fluorescent dye for strains not amenable
for expression of foreign proteins, combined with fluor-
escence molecular tomography (FMT) (Fig. 1;
Additional file 1: Movie S1), overcomes many of these
limitations by offering the possibility to do simultaneous
3D imaging of different microbes in mouse intestine for
non-invasive, real-time, in vivo analysis of host-microbe
and microbe-microbe interplay.
Results
Movement of bacteria along the GI tract can be
monitored in 3D using fluorescently-labeled bacteria
E. coli Nissle 1917 bacteria were labeled with a fluores-
cent dye, fed to mice, and monitored over time using in
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vivo FMT (Fig. 2). Images show the bacteria progressing
through the small intestine. FMT also permits the
generation of temporal 3D images of bacterial localization
as shown by FMT images of mice imaged without reposi-
tioning in between scans. Overlaying images from differ-
ent time points reveals initial stomach emptying and 3D
localization of bacteria over time (Fig. 3).
Dual-color FMT imaging reveals the differences in
intestinal localizations of labeled bacterial strains
The E.coli K12-derived TOP10 bacteria, stably express-
ing the near far-red fluorescent protein Katushka, and
the fluorescently-labeled E. coli Nissle 1917 were co-fed
to mice and imaged 24 h after feeding to determine their
differential localization within the digestive tract (Fig. 4a).
Merged images show that, while Nissle 1917 is predom-
inantly located in the upper digestive tract, the TOP10
bacteria are present primarily at the lower part of the
intestine. Regions of fluorescence were confirmed by ex
vivo planar fluorescent imaging of the intestinal tract
(Fig. 4b). Ex vivo analyses of the excised digestive tract
showed Nissle 1917 bacteria in the duodenum and
jejunum/early ileum while the TOP10 bacteria were
primarily located in the terminal ileum and colon.
FMT imaging allows quantitative monitoring of spatially-
resolved bacteria in the GI tract
Movement of bacteria along the GI tract was analyzed
by placing volumes of interest (VOIs) on mice fed with
fluorescent bacteria and monitored in vivo over time
(Fig. 5a). VOIs were quantified at each time point to
assess E. coli TOP10 and Nissle 1917 strains progression
through the GI-tract (Fig. 5b). Twenty-four hours after
feeding, a substantial retention of Nissle 1917 in the
upper and lower small intestine (VOIs 1 and 2, respect-
ively) was observed, whereas the majority of the TOP10-
derived fluorescence was found in the area spanning the
terminal ileum (VOI 2), and cecum/colon (VOI 3). The
weakest fluorescent foci observed by FMT for E. coli
Nissle 1917, stained with a lipophilic membrane dye,
and TOP10, expressing the Katushka fluorescent pro-
tein, corresponded to approximately 3 × 105 and 1 × 106
colony forming units (cfu), respectively.
Discussion
Here we present data on a fluorescence-based dual-color
imaging system for bacteria in mouse intestine. In this
system, one bacterial strain was metabolically labeled
with the near far-red fluorescent protein Katushka [30],
while the second bacterial strain was surface-labeled
with an infrared red membrane-dye. The usage of
fluorescent reporters in the study of microbial ecology in
the intestine has been hampered by the autofluorescent
and light absorbing properties of several tissues, e.g. the
high absorbance by hemoglobin in the visible spectrum
(< 650 nm) and by lipids and water in the infrared range
(> 900 nm). The detrimental effect of tissue autofluores-
cence in intestinal whole body imaging is exemplified by
the usage of low wavelength green fluorescent protein
(GFP) as a reporter, where at least 1011 colony forming
Fig. 1 Non-invasive 3D dual-color imaging of fluorescent bacteria in murine intestine. 3D imaging combined with 2D imaging and post mortem
histopathology allows assessment of the dynamic relationships between different bacterial populations and their locations in organ, tissue and
cell level. 2D imaging and histopathology can be used to calibrate and locate the tissues in dynamic real-time settings
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units (cfu) were required to obtain bacterial GFP signal
in vivo from mouse intestine [31]. Given that the
physiological levels of major species in the colon are in
the range of 109–1010 cfu/g digesta, development of
more sensitive reporter systems has been warranted.
Tissue absorbance and autofluorescence (which are sub-
stantially diminished at higher wavelengths), combined
with light refractive properties governing tissue penetra-
tion, create an optimal biological imaging window in the
red/infrared area of the spectrum, where in vivo, whole-
body, light-based imaging is maximized. Attempts to
answer this demand have included introduction of differ-
ent red-fluorescent proteins from multiple sources, such
as mCherry and DsRed [32, 33], but the relative fluores-
cence intensities of these proteins have been rather
disappointing in in vivo imaging applications. These sen-
sitivity-related issues were overcome by the introduction
of bioluminescent labeling of bacteria for whole animal
intestinal imaging in 2006 [34], when Wiles et al. trans-
formed the enteric mouse pathogen Citrobacter roden-
tium with a plasmid harboring the luxCDABE gene
cassette [35]. This bioluminescence-based in vivo im-
aging strategy was sensitive enough to detect lux-labeled
bacteria in the murine intestine after oral cavage with
109 cfu bacteria, which is in the range of densities
determined for single bacterial species in the mammal
intestine, and has been the preferred choice for in vivo
imaging of intestinal microbes ever since. There are,
however, several important limitations in the usage of
bioluminescence: the resolution of luminescence
imaging does not allow visualization of individual
bioluminescent bacterial cells. Furthermore, even if de-
tection of single cells was not desired, bioluminescence
is dependent on cellular NAPDH and can therefore only
be used to detect metabolically active bacteria, thus ex-
cluding the possibility for most ex vivo microscopical
analyses of bioluminescently-labeled bacteria in tissue
samples. Most importantly, although bioluminescent
reporter systems with different light spectra have been
described [23, 36], the spatial information of murine gut
colonization using bioluminescent dual-color imaging
remains scarce, since according to our knowledge no
bioluminescent dual-color imaging system suitable for
3D imaging of GI-tract bacteria has been reported to
date. In contrast, current advances in fluorescence im-
aging of GI-tract bacteria have addressed many of these
shortages, e.g. simultaneous dual-color 3D imaging of
different bacteria utilizing expression of spectrally differ-
ent infrared fluorescent proteins has been presented
recently [25]. However, usage of infrared fluorescent pro-
teins not only requires addition of exogenous biliverdin as
a co-factor for fluorophore maturation and thus develop-
ment of fluorescence, but is also limited to bacterial
strains for which molecular cloning tools are available.
Here, we seek to overcome the present shortcomings
encountered with bioluminescent labeling and earlier
fluorescent approaches by combining metabolic labeling
with the far-red fluorescent protein Katushka with a
membrane-labeling IR dye, thus combining genetic
labeling with universal membrane-labeling suitable for
all cultivable bacteria. We chose the K12-derivative
TOP10 as a representative of commensal E. coli, and
Nissle 1917 strain for its well characterized probiotic
properties. The strain K12 belongs to the E. coli
Fig. 2 Fluorescently-labeled E. coli Nissle 1917 can be tracked in vivo
over time after feeding. Mice were fed fluorescently-labeled E. coli
Nissle 1917 and imaged over time by FMT. Images were acquired at
10, 30, 45, 60, 80, 95, 110 and 120min after feeding and show
isosurface rendering of fluorescent signal
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reference strain collection [37] major phylogenetic
lineage A, that comprises mostly commensal isolates,
whereas Nissle 1917 strain falls into the phylogroup B2
containing many of the extraintestinal pathogenic E. coli
(ExPEC) strains [38]. A common feature of representa-
tives of the B2 group is the prevalence of certain viru-
lence-associated genes (e.g. fimbriae, capsular antigens,
α-hemolysin, and colibactin), and it has been noted that
accumulation of these pathogenicity determinants corre-
lated positively with intestinal residency time of com-
mensal isolates [38]. Interestingly, it has been shown
that the presence of the colibactin-encoding pks-island
associates with long-term colonization as compared with
intermediate-term or transiently colonizing E. coli iso-
lates [39]. Furthermore, the ability of the Nissle 1917
strain to exert its probiotic effects cannot be separated
from its capability to produce active colibactin, blurring
the thin lines between probiocity, commensalism, and
pathogenicity [40].
The excitation and emission characteristics of
Katushka (588 nmex, 635 nmem) allow it to be used for
dual-color imaging in combination with several dyes
fluorescing in the infrared region. In whole body
imaging, the near far-red and IR fluorescent regions are
superior over lower wavelengths due to minimal tissue
autofluorescence and light absorption at these
wavelengths. Here we show that FMT imaging of live
mice fed with fluorescently-labeled bacteria can be used
for tracking the bacteria over time in 3D, and for iden-
tifying differentially moving bacterial foci with 3D
image overlays. We additionally show, that mice fed
simultaneously with two different E. coli strains, Nissle
1917 and TOP10, show discrete localizations and
colonization time and patterns within the GI tract and
can easily be distinguished using fluorescence imaging.
And finally, the bacterial movement through the GI-
tract can be quantified showing a more rapid progres-
sion for K12-derived TOP10 bacteria and prolonged
retention for Nissle 1917 strain known to possess high
capacity for long-term colonization of the gut [41].
Total GI fluorescence was used to quantify the mini-
mum intensity foci observed in fed mice and was found
to correlate with ~ 3 × 105 cfu. This estimation reflects
the smallest observed colonization site and does not
necessarily reflect the absolute lowest detection limit of
FMT. It is interesting to note that fluorescence at
intensities of 100 fold lower values than those reported
in this study are capable of detection by FMT. It is also
Fig. 3 In vivo imaging using FMT allows for temporal and 3D spatial
monitoring of bacterial progression. Mice fed with fluorescent E. coli
Nissle 1917 were imaged over time without repositioning.
Reconstructed images were merged allowing both temporal and 3D
spatial monitoring of bacteria progression
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important to note that estimations derived here make
the false assumption that the entire bacterial load fed
to the mice survive passaging through the stomach and
enter then GI-tract. These facts suggest our estimated
3 × 105 cfu threshold could reflect a significant overesti-
mation. Sensitivity will also be affected by the tissue
depth from which the signal originates, as well as the
wavelength of fluorescent molecule used, with longer
wavelengths being associated with more efficient tissue
penetration.
Conclusion
The 3D fluorescent imaging method for bacteria in
mouse intestine presented here should find wide usage
in the study of many aspects of intestinal microbial
ecology. Being quantitative and dual-colored, it allows
simultaneous monitoring and enumeration of different
bacterial strains in the distinct topological parts of the
intestine, and by being non-invasive and real-time, it
substantially reduces the number of animals needed to
achieve this goal. Most importantly, even though the
repertoire of cultivable human gut microbiota members
exceeds 1000 nowadays, most of them still remain non-
transformable, thus necessitating usage of non-genetic
labeling methods. As such, the method described herein
represents a major development paving the way for
increasing our knowledge of the highly complex host-
microbe and microbe-microbe interactions taking place
inside the dynamic milieu of the mammal intestine.
Methods
Bacterial strains and labeling
Synthetic DNA containing Katushka fluorescent protein
encoding gene under the control of the LeuS-promoter
was ordered from GeneArt (ThermoFisher Scientific).
This DNA fragment was cloned into the plasmid pLEB124
using standard molecular cloning protocols. The ligation
product was transformed into the K12-derived E. coli
strain TOP10 (Invitrogen) to produce a Katushka-express-
ing, near far-red fluorescing TOP10 strain. E. coli Nissle
1917 cells were labeled with the CellVue Burgundy Cell la-
beling kit (Ebioscience, Frankfurt, Germany). For mouse
experiments the bacteria were grown overnight at 37 °C
on LB-agar (Nissle 1917) or on LB-agar supplemented
with 200 μg/ml erythromycin (Katushka-expressing
TOP10), and washed once with phosphate buffered saline
(PBS) prior to feeding to the mice.
Fig. 4 Mice co-fed with colonizing and non-colonizing bacteria show differential localization 24 h after feeding. Mice were co-fed colonizing,
fluorescently-labeled E. coli Nissle 1917 and the TOP10 bacteria constitutively expressing the fluorescent protein Katushka. 24 h after feeding, FMT
images show a distinct localization pattern with the Nissle 1917 bacteria found within the upper digestive tract while the TOP10 bacteria are
present much lower within the mice (a). Ex vivo analyses of the intestinal tract by NightOwl imaging show substantial amounts of Nissle 1917
cells present in the early ileum while the TOP10 bacteria are more confined to the terminal ileum and colon (b)
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Animal experiments
10 week old C57BL/6 albino mice (in mixed sex relation-
ships) were used from in-house breeding. The breeding
animals were acquired at Charles Rives Laboratory
(Sulzfeld, Germany). All animals were kept in a
temperature and humidity-controlled environment, with a
12 h light/dark cycle, with access to food and water ad
libitum. Animal experiments and care were in accordance
Fig. 5 3D in vivo imaging shows increased retention of colonizing bacteria in the early digestive tract compared with non-colonizing bacteria. Mice
fed with fluorescently-labeled Nissle 1917 or Katushka-expressing TOP10 were imaged by FMT over time to track the progression of the bacteria (a).
VOIs approximating the stomach through upper small intestine (1), lower small intestine (2), and cecum/colon (3) were placed on 3D reconstructed
images. Dashed boxes represent VOIs placed towards the dorsal side of the mouse while solid boxes represent regions in the ventral side. (b)
Fluorescences of individual VOIs were quantified and distribution of each bacteria over the 3 selected regions were determined. The Nissle 1917 shows
preferential retention in regions 1 and 2 over the 24 h period while the TOP10 progresses through the digestive tract with time and is primarily found
in regions 2 and 3 after 24 h
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with the guidelines of institutional authorities and ap-
proved by the Ethics Committee for Animal Experiments
at Christian-Albrechts-Universität-zu-Kiel [approval
number 312–7224.121-17 (46–3/13)]. For imaging experi-
ments, the mice (n = three per group) were fed 5 × 107 cfu
E. coli cells suspended into 50 μl PBS. Mice were anesthe-
tized with intraperitoneal injections of 80mg/kg ketamine
(Aveco Pharmaceutical, IA) and 0.5mg/kg dorbene (Pfizer,
Berlin, Germany). For long-term anesthetization, add-
itional half-dose administrations of ketamine and dorbene
were given upon initial signs of waking. At the end of the
experiment, all mice were killed by overdose of anesthesia.
Imaging
In vivo imaging was done using fluorescence molecular
tomography on a FMT2500LX (Perkin Elmer, MA).
Reconstructed images were analyzed and volumes of
interest (VOIs) placed using the TrueQuant software. Ex
vivo imaging was done using the NightOwl planar
imaging system and Indigo software (Berthold Technolo-
gies, Bad Wildbad, Germany). Merged images were
prepared using ImageJ. Calibration of the FMT for lipo-
philic-stained and Katushka-expressing bacterial cells
was determined by averaging the total fluorescence of
the GI tract from all images taken within 2 h of feeding
(before any significant clearance of the bacteria could
occur) and setting that equal to the initial bacterial feed-
ing (5 × 107 cfu). Sensitivity was assessed by quantifying
the foci with the minimal fluorescent intensity.
Additional file
Additional file 1: Movie S1. 3D video of mouse fed with fluorescent
bacteria. (WMV 651 kb)
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